Physicians' Academy for Cardiovascular Education

Management of hyperkalemia in CKD and HFrEF

15' education - Nov. 27, 2023 - George L. Bakris, MD, David Bushinsky, MD, and Lars Lund, MD

Improving postpartum BP control has long-term benefits after hypertensive pregnancy

3' education - Nov. 20, 2023 - Paul Leeson, MD, PhD

Top 3 observations of the first-in-human study with novel PCSK9 base editing medicine

3' education - Nov. 16, 2023 - Andrew Bellinger, MD, PhD

Results with novel FXI inhibitor in AF set the stage for phase 3 trials

3' education - Nov. 16, 2023 - Christian Ruff, MD

An option for lowering BP beyond prescribing an additional pill

3' education - Nov. 16, 2023 - Florian Rader, MD

Long-term durability of BP control with renal denervation

3' education - Nov. 16, 2023 - Michael Bloch, MD

Clinical implications of the evidence from IV iron trials in HF

10' education - Nov. 15, 2023 - Stefan Anker, MD, PhD, Robert Mentz, MD, and Piotr Ponikowski, MD, PhD

Benefit of TTR-stabilizer starts as early as 3 months in transthyretin amyloid cardiomyopathy

3' education - Nov. 15, 2023 - Ahmad Masri, MD

Novel RNAi therapeutic lowers blood pressure in patients with hypertension

3' education - Nov. 13, 2023 - George Bakris, MD

GLP-1RA for CVD risk reduction in obesity and overweight - Clinical implications

3' education - Nov. 13, 2023 - Michael Lincoff, MD

Novel insights on the importance of dietary sodium reduction

3' education - Nov. 13, 2023 - Deepak Gupta, MD

Lp(a) below detection limit with highest dose of siRNA in phase 1 trial

3' education - Nov. 13, 2023 - Steven Nissen, MD

Three fascinating new strategies for lipid management

3' education - Nov. 13, 2023 - Karol Watson, MD, PhD

Lower stroke risk with DOAC vs. aspirin in subclinical atrial fibrillation

3' education - Nov. 12, 2023 - Jeff Healey, MD

Two different treatment pathways for stable coronary artery disease

3' education - Nov. 11, 2023 - Rasha Al-Lamee, MD, PhD

GLP-1RA reduces risk of CV events associated with overweight and obesity

3' education - Nov. 11, 2023 - Michael Lincoff, MD

Improvement in health outcomes with GLP-1RA in patients with overweight or obesity with CVD

3' education - Nov. 11, 2023 - Ania Jastreboff, MD, PhD

2023 ESC Guideline Updates: Where are we with iron deficiency?

10' education - Oct. 23, 2023 - Giuseppe M.C. Rosano, MD, PhD, Marco Metra, MD, and Gianluigi Savarese, MD, PhD

A practical look at cardiorenal protection for CKD in T2D: Applying recent data

15' education - Oct. 19, 2023 - Carolyn Lam, MD, PhD, Maria Luiza Caramori, MD, PhD, Ana Maria Cebrián-Cuenca, MD, PhD, and Pam Taub, MD

A multidisciplinary approach to managing potassium levels in patients with HF when optimizing RAASi therapy

10' education - Oct. 18, 2023 - Antoni Bayés-Genís, MD, PhD, and Patrick Rossignol, MD, PhD

9 stages of developing and evaluating predictive AI models to inform clinical decision-making

Literature - Nov. 28, 2023 - Hassan N, et al. - BMJ Health Care Inform 2023

A road map consisting of 9 stages for the development and evaluation of AI predictive models was published recognizing the challenges that clinicians may face and providing them with practical tips to manage these challenges.

Elderly people also benefit from lipid-lowering therapy for primary prevention

Literature - Nov. 27, 2023 - Andersson NW, et al. - J Am Coll Cardiol. 2023

In a Danish cohort study, individuals aged ≥70 years achieved a similar relative risk reduction of major vascular events with lipid-lowering therapy for primary prevention of CVD as those aged <70 years.

Having multiple non-cardiac comorbidities does not limit optimization of HF therapies

Literature - Nov. 27, 2023 - Chioncel O, et al. - Eur J Heart Fail. 2023

In hospitalized acute HF patients, the number of non-cardiac comorbidities did not limit rapid uptitration of oral HF therapies, nor influence the beneficial effects of high-intensity care on 180-day HF rehospitalization or all-cause mortality compared with usual care.

Management of hyperkalemia in CKD and HFrEF

15' education - Nov. 27, 2023 - George L. Bakris, MD, David Bushinsky, MD, and Lars Lund, MD
What are you missing when treating your patients with heart failure and CKD become hyperkalemic? Experts discuss ways to avoid gaps in care.

What are you missing when treating your patients with heart failure and CKD become hyperkalemic? Experts discuss ways to avoid gaps in care.

Phase 3 study with FXIa inhibitor stopped early due to inferior efficacy

News - Nov. 21, 2023

The OCEANIC-AF study will be stopped early due to a lack of efficacy. The study investigates the effects of FXIa inhibitor asundexian compared to apixaban on the risk of stroke and systemic embolism in patients with AF at risk of stroke.

Optimizing postpartum anti-hypertensive therapy improves long-term BP control after hypertensive pregnancy

News - Nov. 20, 2023

AHA 2023 In the POP-HT trial, self-monitoring of BP in combination with physician guided anti-hypertensive medication adjustment during the first 6 weeks postpartum led to improvements in BP up to 9 months after a hypertensive pregnancy.

Improving postpartum BP control has long-term benefits after hypertensive pregnancy

3' education - Nov. 20, 2023 - Paul Leeson, MD, PhD
**AHA 2023** What are the long-term effects of a postpartum physician-guided BP lowering strategy in woman after hypertensive pregnancy? Paul Leeson shares the results of the POP-HT trial.

AHA 2023 What are the long-term effects of a postpartum physician-guided BP lowering strategy in woman after hypertensive pregnancy? Paul Leeson shares the results of the POP-HT trial.

siRNA targeting TTR improves functional capacity in ATTR cardiac amyloidosis

Literature - Nov. 20, 2023 - Maurer MS, et al. - N Engl J Med. 2023

In the APOLLO-B trial, 12-month treatment with patisiran resulted in preserved functional capacity, health status, and quality of life in patients with transthyretin (ATTR) cardiac amyloidosis compared with placebo.

Phase 3 trial does not confirm efficacy of PCSK9 siRNA in HoFH

Literature - Nov. 20, 2023 - Raal F, et al. - Circulation. 2023

The ORION-5 trial, in which 56 patients with homozygous familial hypercholesterolemia (HoFH) were treated with inclisiran or placebo, did not meet its primary endpoint of LDL-c reduction at 150 days. The PCSK9 level did decrease in the inclisiran group.

Top 3 observations of the first-in-human study with novel PCSK9 base editing medicine

3' education - Nov. 16, 2023 - Andrew Bellinger, MD, PhD
**AHA 2023** Andrew Bellinger talks about VERVE-101, a novel base editing medicine which makes a single base pair change in the //PCSK9// gene to lower PCSK9 and LDL-c. He shares three important observations of the first-in-human study with VERVE-101 in patients with HeFH and ASCVD.

AHA 2023 Andrew Bellinger talks about VERVE-101, a novel base editing medicine which makes a single base pair change in the PCSK9 gene to lower PCSK9 and LDL-c. He shares three important observations of the first-in-human study with VERVE-101 in patients with HeFH and ASCVD.

Results with novel FXI inhibitor in AF set the stage for phase 3 trials

3' education - Nov. 16, 2023 - Christian Ruff, MD
To the suprise of the investigators of the AZALEA-TIMI 71 trial, the Data Safety Monitoring Committe recommended early termination of the phase 2 trial with the FXI inhibitor abelacimab in patients with AF. What are the findings of an interim analysis?

AHA 2023 To the suprise of the investigators of the AZALEA-TIMI 71 trial, the Data Safety Monitoring Committe recommended early termination of the phase 2 trial with the FXI inhibitor abelacimab in patients with AF. What are the findings of an interim analysis?

An option for lowering BP beyond prescribing an additional pill

3' education - Nov. 16, 2023 - Florian Rader, MD
**AHA 2023** “Non-adherence is a huge problem and probably the biggest barrier when it comes to hypertension control” says Florian Rader. He discusses the possibilities of ultrasound renal denervation in hypertension care.

AHA 2023 “Non-adherence is a huge problem and probably the biggest barrier when it comes to hypertension control” says Florian Rader. He discusses the possibilities of ultrasound renal denervation in hypertension care.

Agenda